Click Here! Click Here!
 
Click Here!
 
 
 

 

 

Prostate cancer

Intermittent vs continuous androgen suppression

David Cuthbert, MD, FRCPC, Fellow, Department of Radiation Oncology, Princess Margaret Hospital and University of Toronto.
Padraig Warde, MB, MRCPI, FRCPC, Professor, Department of Radiation Oncology, Princess Margaret Hospital and University of Toronto; Deputy Head, Radiation Medicine Program, Princess Margaret Hospital, Toronto.

To view the complete article click here (pdf format)

 

TRIAL SUMMARY: Quality of life benefits linked with
intermittent androgen suppression

 

To view the complete article click here (pdf format)

 
Back to Top of Page 

 

 
 

Canadian Association Of Radiation Oncology (CARO)
September 7-11, 2011, Winnipeg, Manitoba.

In Brief

Already known

  • Androgen deprivation therapy is effective in patients with prostate cancer who relapse after primary treatment.
  • Until now, the standard strategy has been continuous treatment until death.

What this study showed

  • An intermittent approach to androgen deprivation therapy is safe and results in improved quality of life for patients when they are off treatment.

Next steps

  • Further research is needed to determine which patients will benefit from this approach, when androgen deprivation therapy should be started in these patients, and the impact of new agents such as abiraterone and MDV1000.
Click Here! Click Here!
© Parkhurst Publishing Privacy Statement
Legal Terms of Use